The capital investment, co-led by Dolby Family Ventures and Tech Coast Angels(TCA), will support Echo in scaling manufacturing, strengthening the company's sales infrastructure, and developing future technologies.
Echo, formerly Echo Laboratories, created the hybrid microscope, Revolve, which combines the functionality of both upright and inverted microscopes to reduce costs, while freeing up laboratory space.
Revolve also leverages tablet and cloud-based technologies to capture and manage image data while delivering a modern, seamless approach to data management and hardware integration.
The global microscopy market is expected to reach over USD 6bn by 2021 (MarketsandMarkets Research), yet new technology has been slow to evolve.
The Revolve's capitalisation of this opportunity through its usability and versatility has been early adopted in top institutions such as Stanford University; University of California, San Francisco; Harvard University; Yale University; 23andME; Pfizer; and the National Institutes of Health.
Echo said its future products will include a higher end model with automation, designed for those in biotech and pharma, as well as an entry-level model for students, educators and those focused on science, technology, engineering, and mathematics.
The company previously raised USD 5m from angel investors, including TCA. Echo won TCA San Diego's Quick Pitch contest in 2016, beating 146 competitors for the USD 15,000 first-place prize. Echo was founded in 2013 and is headquartered in San Diego.
Echo, formerly Echo Laboratories, was founded in 2013 and is headquartered in San Diego.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA